Information Provided By:
Fly News Breaks for March 8, 2017
BCRX
Mar 8, 2017 | 08:26 EDT
JMP Securities analyst Liisa Bayko quotes an expert as saying that BioCryst's BCX7353 significantly reduced the number of hereditary angioedema attacks. The expert agrees with the company's assertion that GI side effects "partially muddled" the data, the analyst states. Bayko estimates that the drug has a 40% chance of being successful and can generate revenue of about $1.9B. Bayko keeps a $10 price target and an Outperform rating on the stock.
News For BCRX From the Last 2 Days
There are no results for your query BCRX